Clinical research

RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 21, 2024
TEC, IPF, University, Idiopathic disease, Division, Assistant, Critical care, Idiopathic pulmonary fibrosis, Chronic obstructive pulmonary disease, Clinical research, Outline of health sciences, Consultant, Respiratory Medicine, Death, SUNY, Observation, Harvard Medical School, COPD, Pharmaceutical industry

CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).

Key Points: 
  • CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).
  • The TEC will help guide the development of RS BioTherapeutics’ first-in-class, steroid-free agent, RSBT-001, in development for Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the world; and Idiopathic Pulmonary Fibrosis (IPF), a rare disease with no cure that claims 40,000 lives each year in the U.S.
  • All have exceptional credentials and are uniquely qualified to help support the development of our first investigational compound, RSBT-001.
  • I’m excited to collaborate with them and look forward to engaging their diverse perspectives spanning the fields of COPD, IPF, and other diseases characterized by pulmonary inflammation.”

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Retrieved on: 
Monday, February 19, 2024
Ophthalmology, ASRS, CTS, Reno 1868 FC, Calendar, Clinical research, Doctor of Pharmacy, Wilmer Ophthalmological Institute, Clinical trial, Geographic atrophy, ASX, University, Society, Organization, AMD, Patient, Data analysis, Johns Hopkins University, Medicine, Retina, Shore, Fellow, Pharmaceutical industry

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor.

Key Points: 
  • MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor.
  • “We are delighted to have Dr. Khanani join Opthea as Chief Medical Advisor,” said Frederic Guerard, PharmD, Chief Executive Officer for Opthea.
  • “Dr.
  • Khanani’s extensive experience and informed perspective, from his work as the principal investigator for numerous clinical trials for retinal diseases, will be invaluable to Opthea.

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Alanine transaminase, HDV, ALT, Clinical research, Cirrhosis, Safety, RNA, CHD, Patient, Clinical trial, Hepatitis, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
  • Initial data are expected in the second quarter of 2024.
  • SOLSTICE is a Phase 2 multi-center, open-label trial designed to evaluate the safety, tolerability, and efficacy of tobevibart and elebsiran in adult participants (age 18 to 69) with CHD infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy.
  • Depending on the cohort, trial participants are receiving multiple doses of tobevibart and elebsiran as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks.

Associated Medical Professionals of NY Revolutionizes Men's Health Care with Groundbreaking New IR Center and BPH Treatment Initiative

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Other Health, Radiology, Pharmaceutical, Surgery, Practice Management, Oncology, Managed Care, General Health, Seniors, Hospitals, Men, Biotechnology, Consumer, Health, Hospital, Urology, Interventional radiology, Physician, Prostate, Clinical research, Risk, BPH, PAE, Patient, A.M.P, Corporation, Prostatic artery embolization, Medical imaging

is an affiliate of U.S. Urology Partners , one of the nation’s largest independent providers of urology and related specialty services.

Key Points: 
  • is an affiliate of U.S. Urology Partners , one of the nation’s largest independent providers of urology and related specialty services.
  • The new initiative will include a collaboration between Associated Medical Professionals of NY and Prostate Centers USA®, furthering A.M.P.
  • Dr. Christopher M. Pieczonka, Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners , stated, “ A.M.P.
  • has long been committed to being the leader in men’s health care , empowering men to live their lives to the fullest.

Radiation Oncology Expert and Cancer Researcher Dr. Daniel Vanderbilt Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Tuesday, February 20, 2024
Technology, Biotechnology, Health, Robotics, Radiology, Pharmaceutical, Surgery, Oncology, Research, Medical Devices, General Health, Hospitals, Science, Clinical Trials, Hospital, Philosophy, Doctor of Philosophy, MD, Physician, Cancer, Prostate, Clinical research, Weill Cornell Medicine, Lung, Radiation oncologist, Breast, NMS, Patient, A.M.P, Radiation, Corporation, MultiCare Health System

is pleased to announce that Daniel B. Vanderbilt, MD, PhD , has joined its care team .

Key Points: 
  • is pleased to announce that Daniel B. Vanderbilt, MD, PhD , has joined its care team .
  • Specialty trained in radiation oncology with a doctorate in cancer cell biology, Dr. Vanderbilt has vast experience in researching, diagnosing and treating cancers utilizing the latest technologies.
  • The Associated Medical Professionals of NY multi-specialty practice spans 19 locations in Central New York, including ten offices and nine hospitals.
  • Dr. Vanderbilt will be based in A.M.P.’s office at 2 Ellinwood Drive in New Hartford, NY 13413.

SEKISUI Diagnostics Receives Emergency Use Authorization for the OSOM® Flu SARS-CoV-2 Combo Test

Retrieved on: 
Tuesday, March 5, 2024
Urinary tract infection, Marketing, Clinical research, HHS, Health, COVID-19, Virus, COVID, Business administration

BURLINGTON, Mass., March 5, 2024 /PRNewswire/ -- SEKISUI Diagnostics, a global medical diagnostics manufacturer, has received EUA clearance for the OSOM Flu SARS-CoV-2 Combo Test for use in professional and home testing settings.

Key Points: 
  • BURLINGTON, Mass., March 5, 2024 /PRNewswire/ -- SEKISUI Diagnostics, a global medical diagnostics manufacturer, has received EUA clearance for the OSOM Flu SARS-CoV-2 Combo Test for use in professional and home testing settings.
  • The OSOM® Flu SARS-CoV-2 Combo Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen.
  • As with other OSOM Rapid Tests, it is made in the USA and supported by a highly skilled technical support team of medical technologists/professionals.
  • "The utility of detecting COVID and Flu on one test is now more important than ever having moved into the endemic phase of COVID.

THE CCRM FERTILITY NETWORK WELCOMES RENOWNED REPRODUCTIVE ENDOCRINOLOGIST LARRY BARMAT, MD

Retrieved on: 
Wednesday, February 28, 2024
Division, MD, Assistant, Physician, Golf, Fertility, IVF, Endometriosis, Tennis, Clinical research, Fibroid, Fertilisation, Health, Patient, Family, Jefferson College, Ironman Lake Placid, Research, Travel, Nursing

NEWARK, Del., Feb. 28, 2024 /PRNewswire/ -- The CCRM Fertility Network, leading pioneers in fertility treatment and research, announced today that Larry Barmat, MD, will be joining the RADfertility Delaware team. Dr. Barmat is double board-certified in Obstetrics and Gynecology, as well as Reproductive Endocrinology and Infertility.

Key Points: 
  • NEWARK, Del., Feb. 28, 2024 /PRNewswire/ -- The CCRM Fertility Network, leading pioneers in fertility treatment and research, announced today that Larry Barmat, MD, will be joining the RADfertility Delaware team.
  • As an accomplished fertility specialist, scientific researcher, and physician leader, Dr. Barmat will work in tandem with CCRM Network physicians and embryologists utilizing cutting-edge proprietary technology and innovative scientific techniques.
  • "I am thrilled to join the CCRM Network and RADfertility team to ensure patients are achieving unparalleled IVF success rates," said Dr. Barmat.
  • Bob LaGalia, CEO of CCRM Fertility, formally announced the addition of Dr. Barmat to the team, stating, "We are thrilled to have Dr. Barmat join the CCRM Fertility family.

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, CIPN, MD, ASCO, Strategic planning, SITC, Clinical research, Chemotherapy-induced peripheral neuropathy, AACR, MBA, Society, Immunology, Patient, Immunotherapy, Head, Medical device

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.

Key Points: 
  • COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.
  • Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization.
  • "We are thrilled to appoint Dr. Arshad as Bexion's Chief Medical Officer," said Scott Shively, Bexion's Chief Executive Officer.
  • Dr. Arshad previously led medical strategies for blockbuster biologic therapies approved for clinical use in major immunology indications and other groundbreaking therapies as Head of Medical Affairs for Immunology at Sanofi, and he served as Chief Medical Officer and Head of Clinical Research at Humanigen, developing novel immune-oncology therapies.

Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires

Retrieved on: 
Monday, February 26, 2024
SSRI, Senior, Champaign–Urbana metropolitan area, Green belt, Management, Clinical research, Kellogg School of Management, MBA, Molecular biology, Psychiatry, Miami University, University, Hologic, RNA, Society, Biomarker, DSM-IV codes, Medicine, Technologist, Novartis, Neurology, Genomics, Exact sciences, IVD

ALBUQUERQUE, N.M., Feb. 26, 2024 /PRNewswire/ -- Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the appointments of Dave Karlander as Chief Commercial Officer and Vishi Srinivasan, Ph.D., as Senior Director of Clinical Research. In these new roles, Karlander will oversee and manage all commercial aspects of the company's operations, including sales, product marketing and managed care; and Dr. Srinivasan will drive the advancement of Circular Genomics' clinical pipeline and strategy for the development of circular RNA-based tests in psychiatric and neurologic disorders.

Key Points: 
  • ALBUQUERQUE, N.M., Feb. 26, 2024 /PRNewswire/ -- Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the appointments of Dave Karlander as Chief Commercial Officer and Vishi Srinivasan, Ph.D., as Senior Director of Clinical Research.
  • In these new roles, Karlander will oversee and manage all commercial aspects of the company's operations, including sales, product marketing and managed care; and Dr. Srinivasan will drive the advancement of Circular Genomics' clinical pipeline and strategy for the development of circular RNA-based tests in psychiatric and neurologic disorders.
  • "I am delighted to welcome both Dave and Vishi to our leadership team at Circular Genomics," said Dr. Paul Sergeant, Chief Executive Officer of Circular Genomics.
  • "Dave's extensive background in commercial operations, including leading several product launches, will be invaluable during this stage at our company.

Pediatrix® Medical Group to Host National Neonatology Meetings Feb. 19-24

Retrieved on: 
Tuesday, February 13, 2024
Health, Consumer, Practice Management, Other Health, Baby, Maternity, Pharmaceutical, Biotechnology, Accreditation, Woman, FAAP, NEO, Research, Accreditation Council, MD, Physician, Health Promotion International, Quality, Pediatrics, Clinical research, Continuing medical education, Life, Conference, ACCME, Infant, Pediatrix Medical Group, Patient, Teaching, MPH, DRH, Child, Education, Nursing

Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized health care for women, children and babies, will host the top meetings in neonatal-perinatal medicine Feb. 19-24 in Las Vegas, Nevada.

Key Points: 
  • Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized health care for women, children and babies, will host the top meetings in neonatal-perinatal medicine Feb. 19-24 in Las Vegas, Nevada.
  • The meetings will host more than 600 combined attendees comprising neonatologists, neonatology fellows, pediatricians, advanced practice nurses and other allied health professionals, in addition to exhibitors and sponsors.
  • As a trusted provider of neonatology services for 45 years, Pediatrix cares for nearly a quarter of infants born in the U.S. that require intensive care.
  • , neonatologist and medical director at Pediatrix Neonatology of San Antonio, NEO continues its longstanding tradition of providing the latest information on key areas of neonatal management.